According to Fortune Business Insights, the global intravenous immunoglobulins (IVIG) market size was valued at USD 14.85 billion in 2025 and is projected to grow from USD 16.04 billion in 2026 to USD 32.37 billion by 2034, exhibiting a CAGR of 8.28% during the forecast period. North America dominated the intravenous immunoglobulins market with a market share of 74.53% in 2025.
The market is witnessing robust growth due to the increasing prevalence of immunological and neurological disorders, rising awareness of immunoglobulin therapies, expanding plasma collection capacity, and growing approvals for new therapeutic indications. Advancements in plasma fractionation technologies and increasing healthcare investments are further supporting market expansion.
Key Market Drivers
Rising Prevalence of Immunodeficiency Disorders
The increasing incidence of primary immunodeficiency diseases and immune-related disorders is driving demand for intravenous immunoglobulin therapies.
Expanding Clinical Applications
Growing use of IVIG for neurological, autoimmune, hematological, and inflammatory diseases is broadening the market's therapeutic scope.
Increasing Plasma Collection and Fractionation Capacity
Investments in plasma collection centers and advancements in plasma processing technologies are improving immunoglobulin supply worldwide.
Market Restraints
Limited Plasma Availability
IVIG production depends on human plasma donations, making supply vulnerable to fluctuations in plasma collection.
High Treatment Costs
The complex manufacturing process and dependence on plasma-derived raw materials contribute to the high cost of IVIG therapies.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/intravenous-immunoglobulins-market-100593
Market Opportunities
Expansion of Approved Therapeutic Indications
Ongoing clinical research evaluating IVIG for additional autoimmune and neurological disorders is expected to create new market opportunities.
Growing Adoption of Home-Based Infusion Therapy
Increasing preference for homecare treatment is supporting demand for convenient IVIG administration and patient-centered healthcare services.
Segmentation
By Indication
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain-Barré Syndrome (GBS)
- Immune Thrombocytopenic Purpura (ITP)
- Multifocal Motor Neuropathy (MMN)
- Others
By Form
- Liquid
- Lyophilized
By End User
- Hospitals
- Clinics
- Homecare
Regional Insights
North America
North America dominated the intravenous immunoglobulins market with a share of 74.53% in 2025. The region benefits from extensive plasma collection infrastructure, advanced healthcare systems, high diagnosis rates of immunological disorders, favorable reimbursement policies, and the presence of leading plasma-derived therapy manufacturers.
Europe
Europe is witnessing steady market growth due to increasing awareness of immunoglobulin therapies, expanding healthcare expenditure, and rising prevalence of autoimmune and neurological diseases.
Asia Pacific
Asia Pacific is expected to register significant growth during the forecast period owing to improving healthcare infrastructure, increasing diagnosis of immunodeficiency disorders, expanding plasma collection activities, and growing access to advanced biologic therapies.
Rest of the World
Latin America and the Middle East & Africa are gradually increasing IVIG adoption as healthcare infrastructure improves and awareness of plasma-derived therapies continues to grow.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/intravenous-immunoglobulins-market-100593
Key Players in the Intravenous Immunoglobulins Market
- CSL Behring LLC
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Kedrion Biopharma Inc.
- Octapharma AG
- Biotest AG
- LFB S.A.
- ADMA Biologics, Inc.
- China Biologic Products Holdings, Inc.
- Bharat Serums and Vaccines Limited
Conclusion
The global intravenous immunoglobulins market is expected to witness strong growth through 2034, driven by the rising prevalence of immunodeficiency and autoimmune disorders, expanding clinical applications, and increasing plasma collection capacity. Continued advancements in plasma fractionation technologies, broader therapeutic approvals, and growing adoption of home-based infusion therapies are expected to create significant growth opportunities for market participants during the forecast period.